Shuttle Pharmaceuticals is a biotechnology and pharmaceutical company headquartered in Rockville, MD, United States. Founded in 2012, the company recently received a significant $4.00M post-IPO debt investment on 12 January 2023. This injection of capital signifies strong investor confidence in Shuttle Pharma’s potential for growth and innovation within the biotech and pharmaceutical industries. The company’s focus on cutting-edge research and development positions it as an attractive opportunity for venture capital firms seeking high-potential investment prospects. As the demand for advanced pharmaceutical solutions continues to rise, Shuttle Pharma’s strategic positioning stands to yield substantial returns for investors in the coming years.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Debt | $4.00M | - | 12 Jan 2023 | |
| Seed Round | $912.50K | - | 30 Jan 2019 |
No recent news or press coverage available for Shuttle Pharmaceuticals, Inc..
We care about your data, and we'd love to use cookies make your experience better.
